Ketamine: Treatment of Depression and Suicidal Ideation or Behavior

Released April 25, 2024

Ketamine: Treatment of Depression and Suicidal Ideation or Behavior

The global impact of depression is profound, affecting individuals across all walks of life, with estimates reaching nearly 300 million people according to the World Health Organization (WHO). Fortunately, ketamine has emerged as a promising therapeutic option. This webinar will provide an evidence-based rationale for the use of esketamine in treating depression and suicidal ideation, equipping healthcare professionals with foundational support for its consideration in patient care. A live Q&A with Dr. Paul M. Kim will follow the presentation.

Topics Covered Include:

• Overview of ketamine/esketamine and glutamate hypothesis of depression
• Esketamine clinical trials
• Future directions and considerations for treating TRD and MDD with suicidal ideation and behavior

FOR MORE INFORMATION

Johns Hopkins Psychiatry Guide: https://www.hopkinsguides.com​

Unbound Medicine: https://www.unboundmedicine.com

About the Presenter

Paul M. Kim, MD, PhD

Paul M. Kim, MD, PhD is an assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine (JHU SOM). He received his medical and doctoral degrees from JHU SOM and completed his psychiatry residency at the Johns Hopkins Hospital. He currently serves as the medical director of the Johns Hopkins Esketamine Clinic and is a managing editor of the Johns Hopkins POC-IT Psychiatry Guide. As a clinician-scientist, he also studies the role of neuroinflammation in neurological and psychiatric disorders.